This commentary addresses the recently announced Philip Morris International (PMI) Foundation for a Smoke-Free World, bringing the perspectives of the leadership of the American Thoracic Society (ATS) (D.J.L., P.T.S., J.A.W., and M.M.); biomedical ethicists (M.K.W. and D.S.G.); a public health school dean (E.J.M.) who facilitated a statement on the foundation by U.S. schools of public health; and the dean (J.M.S.) of a school of public health that signed onto the statement, who has also contributed to multiple reports of the U.S. Surgeon General on smoking and health. By policy, the ATS journals do not accept manuscripts supported by tobacco industry funds, and to date, 19 schools of public health have agreed not to accept funds from the PMI foundation. The announcement of the PMI foundation has already incited controversy and discussion regarding its intent and the degree of separation from PMI, as well as regarding the probity of engagement with it by the broad community of tobacco control researchers and practitioners. Derek Yach, its founding director, is a wellknown figure in tobacco control, but his reassurances on these points have met with skepticism by some (1) .
The tobacco control community is wary of the foundation because of the long history of industry support for research to obfuscate scientific evidence, first on active smoking and then on passive smoking. In 1954, as the U.S. tobacco industry began its well-documented strategy of fraud and misrepresentation, it founded the Tobacco Industry Research Committee, later the Tobacco Research Council (2) . Much of the funded research was intended to point away from smoking as a cause of disease, and a stream of "special" projects had the purpose of undermining the emerging findings on active smoking as causing a lengthening series of diseases. The founding of the Center for Indoor Air Research in 1988 was similarly motivated, and the tactics were the same.
The PMI foundation is launched at a moment of change in the array of tobacco products with the emergence of electronic nicotine delivery systems, including electronic cigarettes and other devices. One of the products is PMI's IQOS (I-QuitOrdinary-Smoking), a "heat not burn" device that delivers a nicotine-containing aerosol by heating and not burning tobacco. The authors see a connection between the emergence of such products and a foundation labeled "smoke free." In this paper, we emphasize the implications of the PMI foundation and its funds for researchers, journals, and academic public health institutions.
We do not address the complex issues of harm reduction around the comparative risks of combustible and noncombustible products for different groups in the population. Recent reports from the U.S. Surgeon General (3) and the National Academy of Medicine (4) have summarized the state of the evidence around electronic cigarettes: the potential for harm reduction for addicted smokers, the risk for electronic cigarettes to increase smoking of cigarettes and use of other tobacco products by adolescents and young adults, and the potential health threat posed by electronic cigarettes. A recent ATS policy statement provides organizational perspective on tobacco harm reduction (5). Relevant to this commentary is how the new PMI foundation might influence the scientific evidence available on these topics and the discussions among stakeholders and decision makers regarding the role of noncombustible products in tobacco control.
The Biomedical Ethics Lens
There are strong ethical justifications to support refusing funds from the PMI foundation. Organizations committed to the advancement of health broadly and public health specifically should not accept funds from the tobacco industry, including the new foundation, on ethical grounds. There are three complementary ethical justifications for taking this absolutist position. First, there is overwhelming empirical evidence that receipt of funds generates motivated bias, which affects behavior in ways that are deleterious to public health, yet are unmanageable using traditional disclosure mechanisms. Second, even if behaviors were unaffected, taking funds from the tobacco industry would threaten public trust in health-promoting organizations, and such mistrust would also be deleterious to public health. Third, in a purely utilitarian calculus, these harms to public health organizations and the communities they serve are not outweighed by any unique benefits of partnering with the tobacco industry.
Motivated bias flows from strong-and deeply human-norms of reciprocity, which arise automatically and often subconsciously when a person receives something of value from another (6-8).
There is a vast literature on this bias, and research relationships involving industry funding have repeatedly been shown to impact-sometimes dramatically-the behaviors of investigators and the research they produce (6) (7) (8) . In this light, one cannot credibly claim that tobacco industry funding would not affect the behaviors of health scientists. It most assuredly would, because health researchers are human. Moreover, because health researchers are human, they probably would not perceive that their choices were being altered (9-11). Although institutions often adopt transparency or disclosure standards in efforts to mitigate the negative effects of motivated bias, evidence suggests that disclosure is not merely ineffective in preventing biased behaviors but might even increase the possibility of them, because the act of disclosure can generate a perceived need for the discloser to subsequently act more in the interest of their industry "partner" in an (often unconscious) effort to counterbalance the assumed effects of the disclosure (12, 13) .
Even if the behaviors of researchers are unaffected by bias, the public very strongly distrusts the tobacco industry (14) , and for very good reasons (2), whereas levels of trust in health organizations are relatively high (15) . Public health organizations would risk tarnishing their trustworthiness by partnering with the tobacco industry.
Finally, meaningful health benefits can and do arise from academic-industry partnerships, particularly if there is an alignment of interest in treating disease and promoting health and well-being. But such complementary alignment with the tobacco industry is elusive, and there is always an ethical obligation to explicitly consider the specific proposed benefits of partnerships together with the recognized risks. Aside from a new revenue line, it is not clear what particular benefits might come from a partnership between a health organization and the tobacco industry, which makes a strictly utilitarian rationale for accepting these funds elusive as well.
The Perspective of Schools of Public Health
In January 2018, 19 deans of public health schools in the United States released a statement that their schools would not currently accept funding or pursue work with the Foundation for a Smoke-Free World. Various considerations went into a school's decision regarding whether to sign the statement. In some cases, schools were unable to obtain the necessary approvals from their universities in a timely manner; we expect additional schools may sign on in the future as conversations unfold.
In the statement, the deans referenced the dismal track records of the tobacco industry and of Philip Morris-a company "whose products have killed millions of people around the world" (16). The deans then cited the unfortunate history of the tobacco industry's "funding 'research' in ways meant to purposefully confuse the public and advance their own interests." The statement quotes from the Framework Convention on Tobacco Control-the world's first public health treaty-that " [t] here is a fundamental and irreconcilable conflict between the tobacco industry's interests and public health policy interests" (17) .
The statement framed the schools' actions in a larger and global context. It noted that the World Health Organization and "other organizations that support smoking prevention and tobacco control efforts in the United States and around the world" had also pledged not to work with the PMI foundation (18) . The statement further noted that the U.S. Food and Drug Administration had recently proposed a framework for regulating nicotine (19) that "holds tremendous potential, as well as potential risks, for public health." The deans wrote, "Success in saving millions of lives will depend on research and policy development untainted by the interests of the tobacco industry."
The statement took exception to claims (20) that the PMI foundation's bylaws and structure met standards for the use of industry funds developed by tobacco control leaders (21) . They wrote, "Major differences include a lack of transparency about how the research agenda was established and the public relations benefits realized by Philip Morris International, even as it increases its marketing of products that predictably will continue to kill millions of people around the world." The statement contrasted the relationship of the foundation to its source of funding with that of the Legacy Foundation (now the Truth Initiative), writing, "Following a settlement of stateinitiated litigation, the tobacco industry was legally required to make payments to Legacy, and the industry did not control any aspect of how these funds were used."
Finally, the deans stated that any revision to their position in the future would require answers to four questions:
1. How is the research agenda established, including whether prevention of nicotine addiction and tobacco use is considered? 2. Is there an impermeable firewall between PMI and the foundation? 3. How will PMI use the foundation for its own benefit? 4. How does PMI demonstrate a true commitment to meaningful change as a company, including the following? a. A specific timeline and milestones for phasing out advertising of cigarettes and cigarettes themselves b. The immediate cessation of activities hostile to the policies advanced by the Framework Convention on Tobacco Control
The Perspective of the ATS Compatible with their mission, the ATS journals do not accept manuscripts that are supported by entities that receive monies from the tobacco industry, a policy that covers the PMI Foundation for a Smoke-Free World. The mission of the ATS is to "improve health worldwide by advancing research, clinical care, and public health in respiratory disease, critical illness, and sleep disorders." To this end, the ATS has promoted education and research aimed at reducing the global burden of respiratory disease for over a century, including tobacco-caused lung diseases. The ATS Tobacco Action Committee's goal is to reduce the impact of tobacco on PUBLIC HEALTH the respiratory disease burden worldwide through advocacy, education, and research. In recent years, the ATS has also issued official documents on tobacco control and treatment, smoking cessation interventions within lung cancer screening programs, and tobacco control initiatives (22) (23) (24) . For decades, the ATS has taken the strongest stance possible in opposing the agenda of the tobacco industry, including the production and distribution of combustible tobacco as well as "less dangerous alternative" products. The ATS has long banned any interaction by the society with the tobacco industry, including activities or presentations that occur at the ATS International Conference. Of equal importance, the ATS journals do not publish manuscripts funded or supported in any way by the tobacco industry. This policy has been in place and strictly enforced since 1995.
The authors suggest that the ATS and other health organizations concur with the World Health Organization's recommendation to "denormalize and, to the extent possible, regulate activities described as 'socially responsible' by the tobacco industry, including but not limited to activities described as 'corporate social responsibility'" (25) . The ATS Tobacco Action Committee might take the lead in considering the organization's approach to addressing this recommendation. The support of the foundation by PMI should be acknowledged as a "corporate social responsibility" activity of the tobacco industry, and by extension, the ATS policy regarding tobacco industry interactions applies to the Foundation for a Smoke-Free World. The World Health Organization's Framework Convention on Tobacco Control has outlined policy options and recommendations on economically sustainable alternatives to tobacco growing, guidance on demand reduction measures, and recommendations aiding implementation of effective measures to reduce exposure to tobacco smoke. We do not see a role for research or recommendations from an industry foundation on these topics.
Conclusions
There is consensus among the authors and the organizations that they represent not to accept funding from the PMI Foundation for a Smoke-Free World, and the ATS journals will not accept papers supported by the foundation. Whether the ethical imperative to eschew the foundation and its outputs can be removed remains uncertain, and any reversal will depend on this latest tobacco industry entity not following the course of its predecessors.
This "socially responsible" effort by PMI pledges $80 million per year for 12 years to the foundation's activities-an amount equivalent to a mere 3 days of the annual expenditure of $9 billion by the tobacco industry on advertising (26) . Let us not be distracted by the new tobacco industry initiative and continue to focus on reducing the burden of tobacco-related premature death and avoidable disease. n
